Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,539,910 papers from all fields of science
Search
Sign In
Create Free Account
PAK4/NAMPT Inhibitor KPT-9274
Known as:
KCP-9274
, KPT-9274
An orally bioavailable inhibitor of both the serine/threonine kinase P21-activated kinase 4 (PAK4) and the nicotinamide adenine dinucleotide (NAD…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer.
J. Trott
,
Omran Abu Aboud
,
+10 authors
R. Weiss
Kidney360
2020
Corpus ID: 216544744
Background Kidney cancer (or renal cell carcinoma, RCC) is the sixth most common malignancy in the United States and is…
Expand
2019
2019
KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative breast cancer cells.
Emma Cordover
,
Janet Wei
,
+8 authors
A. Minden
Chemical Research in Toxicology
2019
Corpus ID: 209482596
Triple negative breast cancer (TNBC) is difficult to treat due to lack of druggable targets. We have found that treatment with…
Expand
2019
2019
PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
G. Mpilla
,
A. Aboukameel
,
+13 authors
A. Azmi
Cancers
2019
Corpus ID: 208626104
Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide…
Expand
2019
2019
Kaempferol as a Potential PAK4 Inhibitor in Triple Negative Breast Cancer: Extra Precision Glide Docking and Free Energy Calculation.
M. Arowosegbe
,
Oluwamuyiwa T Amusan
,
+15 authors
Patrick E Obasieke
Current Drug Discovery Technologies
2019
Corpus ID: 201618892
BACKGROUND P-21 activating kinase 4 (PAK4) is implicated in poor prognosis of many human tumors, particularly in triple negative…
Expand
2018
2018
Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia
Na Li
,
Michael A. Lopez
,
+14 authors
M. Fulciniti
Clinical Cancer Research
2018
Corpus ID: 52192304
Purpose: p21-activated kinase 4 (PAK4) plays a significant biological and functional role in a number of malignancies, including…
Expand
Review
2018
Review
2018
Inhibitors of the p21 Activated Kinases
Namrata Sampat
,
A. Minden
Current Pharmacology Reports
2018
Corpus ID: 4484931
This review article provides an overview of some of the inhibitors that have been generated against the p21-activated kinases…
Expand
2017
2017
Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease.
Vicki J. Hwang
,
Xia Zhou
,
+10 authors
R. Weiss
Kidney International
2017
Corpus ID: 3750570
2017
2017
Abstract LB-308: KPT-9274 inhibits cellular NAD and synergizes with doxorubicin to treat dogs with lymphoma
C. London
,
Megan E Brown
,
+8 authors
E. Baloglu
2017
Corpus ID: 80495380
Nicotinamide adenine dinucleotide (NAD), an essential metabolite and cofactor of several biological processes (e.g. genomic…
Expand
Highly Cited
2016
Highly Cited
2016
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma
A. Aboukameel
,
I. Muqbil
,
+7 authors
A. Azmi
Molecular Cancer Therapeutics
2016
Corpus ID: 4447391
The p21-activated kinase 4 (PAK4) is a key downstream effector of the Rho family GTPases and is found to be overexpressed in…
Expand
2016
2016
Abstract 1864:In vivoefficacy of the PAK4 allosteric modulator KPT-9274 against a triple-negative breast cancer model
Chetan K Rane
,
W. Senapedis
,
E. Baloglu
,
S. Shacham
,
A. Minden
2016
Corpus ID: 57500459
The p21-activated kinases (PAK) belong to a family of serine threonine kinases that promote cell survival and play an important…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE